Gail J. Roboz
NewYork–Presbyterian Hospital
444 Papers
1.6K Citations
Gail J. Roboz is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 53, co-authored 339 publications. Previous affiliations of Gail J. Roboz include Cornell University & Boston Medical Center.
Chat about Author
Papers
A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients With Refractory Leukemia
Usama Gergis,Ellen K. Ritchie,Gail J. Roboz,Joseph M. Scandura,Sebastian Mayer,Tomer M Mark,Tsiporah B. Shore,Usama Wissa,Eric J. Feldman +8 more
2
S170: myelodysplastic neoplasms (mds) classification from who 2017 to who 2022 and icc 2022): an expanded analysis of 7017 patients on behalf of the international consortium for mds (icmds)
Rami S. Komrokji,Somdeb Ball,Giulia Maggioni,Erica Travaglino,Najla Al Ali,Pierre Fenaux,Uwe Platzbecker,Valeria Santini,Maria Diez Campelo,Torsten Haferlach,Avani Mohan Singh,Akriti G Jain,Luis E. Aguirre,Sara Tinsley,Zaker Schwabkey,Onyee Chan,Zhuoer Xie,Andrew M. Brunner,Andrew T. Kuykendall,John M. Bennett,Rena Buckstein,Rafael Bejar,Jan Philipp Bewersdorf,Hetty E. Carraway,Amy E. DeZern,Elizabeth A. Griffiths,Stephanie Halene,Robert P. Hasserjian,Sanam Loghavi,Olatoyosi Odenike,Mrinal M. Patnaik,Gail J. Roboz,Maximillian Stahl,Mikkael A. Sekeres,David P. Steensma,Michael R. Savona,Justin Taylor,Ming Xu,Kendra Sweet,Jeffrey E. Lancet,Alan F. List,Eric Padron,David A. Sallman,Amer M. Zeidan,Matteo G. Della Porta +44 more
TL;DR: MDS-MLD (n= 610, 28%) had shorter LFS (41.4 vs. 74.2 mo, P< 0.01) and OS (49.5 vs. 79.4 mo) than SLD (n), which was similar to previous studies of this type.
2
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
Marina Konopleva,Monique Dail,Naval Daver,Jacqueline S. Garcia,Brian A. Jonas,Karen W.L. Yee,Kevin R. Kelly,Norbert Vey,Sarit Assouline,Gail J. Roboz,Stefania Paolini,Daniel A. Pollyea,Agostino Tafuri,Joseph Brandwein,Arnaud Pigneux,Bayard L. Powell,Pierre Fenaux,Rebecca L. Olin,Giuseppe Visani,Giovanni Martinelli,Maika Onishi,Jue Wang,Weize Huang,Diana Ronai Dunshee,Habib Hamidi,Marion G. Ott,Wan-Jen Hong,Michael Andreeff +27 more
TL;DR: Venetoclax-cobimetinib showed limited preliminary efficacy similar to single-agent venetoclax, but with added toxicity, and the findings will inform future trials of BCL-2/MAPK pathway inhibitor combinations.
2
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Guillermo Montalban-Bravo,Elias Jabbour,Caleb A. Class,Nicholas J. Short,Rashmi Kanagal-Shamanna,Tapan M. Kadia,Gautam Borthakur,Naveen Pemmaraju,Koji Sasaki,Zeev Estrov,Jorge E. Cortes,Farhad Ravandi,Yesid Alvarado,Rami S. Komrokji,Mikkael A. Sekeres,David P. Steensma,Amy E. DeZern,Gail J. Roboz,Hui Yang,Hagop M. Kantarjian,Guillermo Garcia-Manero +20 more
TL;DR: The long-term follow up of a phase 2 study of azacitidine or decitabine for pts with MDS and chronic myelomonocytic leukemia with low or intermediate-1 IPSS risk score compared favorably with expected outcomes in pts with intermediate and high-risk with no significant differences in patients with low risk category.
2
Midostaurin in Adults with Newly Diagnosed FLT3-Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy: Update from the Radius-X Midostaurin Expanded Access Program
Alexander E. Perl,Kendra Sweet,Gail J. Roboz,Stephen A. Strickland,Mark R. Litzow,Gaetano Bonifacio,Kelly Haines,Alysha Barbera,Das Purkayastha,Andrew Dalovisio +9 more
TL;DR: RDIUS-X is an expanded treatment protocol designed to provide access to midostaurin during the US Food and Drug Administration's review process and to extend the understanding of the safety and tolerability of midstaurin in patients with newly diagnosed FLT3-mut+ AML.
2